(Q33341143)

English

Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

object named as

Jeff Szer

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

author name string

John F Seymour

1

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Andrew P Grigg

2

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Richard M Fox

4

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

language of work or name

0 references

publication date

1 February 2002

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

94

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

585-593

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

High-dose cytosine arabinoside in previously treated patients with poor-prognosis non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Cisplatin resistance and DNA repair

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Hematopoietic stem cells and aging

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

High-dose cytosine arabinoside in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Multiple cycles of aggressive chemotherapy prior to autologous peripheral stem cell transplantation for lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Peripheral blood CD34+ cell count reliably predicts autograft yield

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

DICE (dexamethasone, ifosfamide, cisplatin, etoposide) as salvage therapy in non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Which treatment for mantle-cell lymphoma patients in 1998?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Effects of cis-diamminedichloroplatinum on DNA incorporation and cytotoxicity of 1-beta-D-arabinofuranosylcytosine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

21 January 2018

FLUDAP: salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10240

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.10240

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33341143&oldid=1959128645"